



February 10, 2022

Company name: SanBio Co., Ltd.
Representative: Keita Mori, Representative Director
and President
(TSE Mothers Code: 4592)
Contact: Yoshihiro Kakutani, Corporate Officer
of Management Administration
(TEL. +81-3-6264-3481)

Revision of Consolidated Earnings Forecast for the Fiscal Year Ending January 2022

SanBio Company Limited (hereafter, “the Company”) hereby announces that it has revised its consolidated earnings forecast for the fiscal year ending January 2022 (February 1, 2021 to January 31, 2022), announced on March 17, 2021 as below.

1. Revision of consolidated earnings forecast for FY1/22 (February 1, 2021 to January 31, 2022)

(Million yen)

	Operating revenue	Operating income	Ordinary income	Net income attributable to owners of parent	Net income per share (yen)
Previous forecast (Announced March 17, 2021)	—	(5,786)	(5,876)	(5,877)	(113.49)
Revised forecast (B)	—	(6,589)	(4,545)	(4,645)	(89.68)
Change (B) – (A)	—	(803)	1,331	1,232	
Rate of change (%)	—	—	—	—	
(Ref.) Results in FY1/21	—	(5,801)	(6,530)	(3,385)	(65.38)

2. Reasons for change

The Company has revised its forecast for operating loss as manufacturing costs, including manufacturing material costs for SB623, exceeded plan. It has also revised the forecast for ordinary loss and net loss attributable to owners of parent due to foreign exchange gains resulting from yen depreciation in relation to foreign currency-denominated loans receivable from the Company’s consolidated subsidiary.

Note: Earnings estimates provided above were calculated based on information available to the Company at the time of the disclosure of this document, and may differ from actual results due to various factors.